List of Excipients in Branded Drug NITROFURANTOIN MONOHYDRATE/MACROCRYSTALLINE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
BluePoint Laboratories	NITROFURANTOIN MONOHYDRATE/MACROCRYSTALLINE	nitrofurantoin monohydrate/macrocrystalline	68001-001	CARBOMER HOMOPOLYMER TYPE B
BluePoint Laboratories	NITROFURANTOIN MONOHYDRATE/MACROCRYSTALLINE	nitrofurantoin monohydrate/macrocrystalline	68001-001	D&C YELLOW NO. 10
BluePoint Laboratories	NITROFURANTOIN MONOHYDRATE/MACROCRYSTALLINE	nitrofurantoin monohydrate/macrocrystalline	68001-001	FD&C BLUE NO. 1
BluePoint Laboratories	NITROFURANTOIN MONOHYDRATE/MACROCRYSTALLINE	nitrofurantoin monohydrate/macrocrystalline	68001-001	FD&C RED NO. 40
BluePoint Laboratories	NITROFURANTOIN MONOHYDRATE/MACROCRYSTALLINE	nitrofurantoin monohydrate/macrocrystalline	68001-001	GELATIN
BluePoint Laboratories	NITROFURANTOIN MONOHYDRATE/MACROCRYSTALLINE	nitrofurantoin monohydrate/macrocrystalline	68001-001	LACTOSE
BluePoint Laboratories	NITROFURANTOIN MONOHYDRATE/MACROCRYSTALLINE	nitrofurantoin monohydrate/macrocrystalline	68001-001	MAGNESIUM STEARATE

Nitrofurantoin Monohydrate/Macrocrystalline Excipient Strategy and Commercial Opportunities

Last updated: October 29, 2026

Nitrofurantoin monohydrate/macrocrystalline is a mature oral antibacterial product with limited active-ingredient exclusivity and substantial generic competition. Commercial value is concentrated in formulation execution: controlling particle-size distribution, dissolution, capsule-fill uniformity, excipient compatibility, supply reliability, and differentiated dosage forms. The strongest opportunities are generally low-risk reformulation, specialty packaging, global supply, and manufacturing improvements rather than new-molecule patenting.

What is nitrofurantoin monohydrate/macrocrystalline?

Nitrofurantoin monohydrate/macrocrystalline is an oral capsule formulation containing two physical forms of nitrofurantoin. The reference product Macrobid contains 100 mg of nitrofurantoin per capsule, composed of approximately 25 mg nitrofurantoin monohydrate and 75 mg macrocrystalline nitrofurantoin.[1]

The formulation is designed for twice-daily administration. The macrocrystalline component dissolves more slowly than conventional nitrofurantoin, while the combined formulation supports systemic exposure with lower dosing frequency than older four-times-daily products.[1]

Attribute	Nitrofurantoin monohydrate/macrocrystalline
Active ingredient	Nitrofurantoin
Dosage form	Oral hard gelatin capsule
Typical strength	100 mg
Reference product	Macrobid
Reference NDA	NDA 20-064
Administration	Twice daily with food
Main indication	Acute uncomplicated urinary tract infection
Therapeutic class	Urinary antibacterial
Primary commercial issue	Generic price competition and bioequivalence execution
Biosimilar exposure	None; this is a small-molecule drug

The product is used for susceptible lower urinary tract infections. It is not appropriate for pyelonephritis or other infections requiring tissue penetration beyond the urinary tract.[1]

What excipients are used in nitrofurantoin monohydrate/macrocrystalline capsules?

The Macrobid label identifies a conventional solid-dose excipient system consisting of a diluent, binder, disintegrant or processing aid, lubricant, glidant, and capsule-shell materials.[1]

Excipient or material	Likely formulation role	Commercial significance
Lactose monohydrate	Filler and bulk-density modifier	Supports capsule fill and powder flow; creates lactose-intolerance and aldehyde-compatibility considerations
Corn starch	Filler and disintegration aid	Helps break up the capsule fill after ingestion
Povidone	Binder and granulation aid	Improves powder cohesion and content uniformity
Magnesium stearate	Lubricant	Controls ejection and tooling friction; excessive levels can slow dissolution
Talc	Processing aid and glidant	Improves flow and reduces adhesion
Carbomer 934P	Matrix or rheology-modifying excipient	May contribute to release control and powder structure
Gelatin	Capsule shell	Creates animal-origin, dietary, and supply-chain considerations
Titanium dioxide	Opacifier	Subject to regional regulatory restrictions and customer preferences
Approved yellow colorants	Capsule identification	Affect regional acceptability and supply continuity

The exact inactive-ingredient composition matters because changes can affect dissolution, powder flow, capsule weight variation, shell performance, and comparative bioavailability. The reference product’s excipient list should be treated as a technical benchmark, not as the only viable formulation.

How should the excipient strategy be designed?

The preferred strategy is to preserve the product’s performance characteristics while improving manufacturability, supply resilience, and market access.

Match the physical properties of the active ingredient

Nitrofurantoin is a low-dose, poorly water-soluble antibacterial. A generic manufacturer must control particle size, surface area, agglomeration, moisture, and polymorphic or solid-state behavior. The monohydrate and macrocrystalline fractions should be characterized separately and as a final blend.

Critical material attributes include:

• Particle-size distribution
• Crystal habit and morphology
• Water content
• Bulk and tapped density
• Flowability
• Specific surface area
• Assay of each physical fraction
• Blend uniformity
• Dissolution profile

Excipient selection should support uniform distribution of the two nitrofurantoin fractions. Excessive segregation during transport or capsule filling can alter dose uniformity and dissolution.

Optimize capsule-fill performance

Lactose, starch, povidone, talc, and magnesium stearate provide a familiar platform, but the system can be improved through particle engineering and excipient grade selection. Direct blending may reduce processing steps, while dry granulation can improve flow and reduce segregation. Wet granulation introduces water and drying controls that may complicate solid-state stability.

The most commercially useful optimization targets are:

1. Lower weight variability during high-speed filling.
2. Reduced powder dust and operator exposure.
3. Lower lubricant sensitivity.
4. Consistent dissolution across manufacturing sites.
5. Reduced dependence on a single excipient supplier.

A formulation that uses fewer excipients can reduce procurement and validation costs, but simplification is only valuable if it maintains bioequivalence and dissolution performance.

Evaluate lactose-free and animal-free alternatives

Lactose-free formulations could address patients and markets where lactose is commercially undesirable. Mannitol, microcrystalline cellulose, dibasic calcium phosphate, and selected starch-based fillers are potential alternatives, subject to compatibility and performance testing.

A vegetarian or plant-based capsule shell could broaden market access compared with gelatin. Hydroxypropyl methylcellulose capsules can improve positioning in certain export markets and eliminate some animal-origin supply concerns. The substitution can also affect moisture transfer, shell brittleness, oxygen exposure, and capsule dissolution.

A shell change is not a cosmetic adjustment. It requires comparative dissolution work and may create a new regulatory filing burden depending on the jurisdiction and the extent of the change.

Manage colorant and titanium dioxide exposure

Colorants provide product identification but create regional complications. Titanium dioxide restrictions and consumer preference for color-free products support evaluation of opaque white, naturally colored, or uncolored shells.

The commercial benefit is strongest for manufacturers pursuing multiple markets with one global presentation. A single shell system can reduce packaging complexity and avoid country-specific colorant substitutions. The risk is that a colorant-free presentation may require additional stability and visual-identification controls.

What formulation patents protect nitrofurantoin monohydrate/macrocrystalline products?

The original commercial protection for nitrofurantoin and legacy capsule formulations has expired or is no longer the principal barrier to entry. The active ingredient was introduced decades ago, and nitrofurantoin products have been marketed as generics for many years.

Current formulation opportunity is more likely to involve new claims directed to:

• Defined particle-size distributions
• Specific ratios of monohydrate to macrocrystalline nitrofurantoin
• Modified dissolution profiles
• Reduced gastrointestinal adverse effects
• Low-moisture manufacturing processes
• Capsule-shell technologies
• Stabilized suspensions or alternative dosage forms
• Pediatric or geriatric delivery systems
• Manufacturing controls that improve content uniformity

These claims face material validity risks. Particle-size and excipient claims can be vulnerable to anticipation or obviousness arguments when the reference product, pharmaceutical compendia, and conventional formulation practices disclose similar features. Patent value is higher when the formulation has a measurable technical effect, such as a clinically meaningful exposure improvement, reduced variability, or a demonstrated stability advantage.

When does nitrofurantoin monohydrate/macrocrystalline lose exclusivity?

Nitrofurantoin monohydrate/macrocrystalline is already a mature generic market. The principal exclusivity periods associated with the reference product have expired, and commercial entry is not generally constrained by new chemical entity exclusivity or pediatric exclusivity.

Exclusivity category	Commercial status
New chemical entity exclusivity	Expired
Original formulation exclusivity	Expired or commercially immaterial
Pediatric exclusivity	Not a current barrier to routine generic entry
Orphan exclusivity	Not applicable
Biosimilar exclusivity	Not applicable
Active-ingredient patent barrier	Not expected to be the principal barrier
Formulation or process patent risk	Must be reviewed product by product

The relevant regulatory question is whether a proposed generic can satisfy the applicable ANDA requirements and avoid unexpired, listed patents or exclusivity attached to the reference product. The FDA Orange Book remains the controlling public source for listed patents and exclusivity information.[2]

What is the Orange Book status of nitrofurantoin monohydrate/macrocrystalline?

Macrobid is an FDA-approved reference product for which abbreviated new drug applications have been developed. The Orange Book identifies approved reference products, dosage forms, strengths, therapeutic equivalence evaluations, and applicable patent or exclusivity data.[2]

For a prospective entrant, the primary Orange Book workstreams are:

• Confirm the current reference product and strength.
• Review listed patents and expiration dates.
• Determine whether any listed patents require a Paragraph IV certification.
• Assess whether the product can use a Paragraph III certification or a Section viii statement.
• Confirm the current therapeutic-equivalence codes for approved ANDAs.
• Check whether any patent delisting or litigation changes the entry date.

A complete patent opinion cannot rely on the historical absence of significant barriers. Orange Book listings, ownership, and litigation positions can change over time.

Are Paragraph IV challenges likely for nitrofurantoin monohydrate/macrocrystalline?

Paragraph IV risk is generally lower for a mature product with limited active-ingredient protection. The main potential targets would be later-issued formulation or method-of-use patents, not the basic nitrofurantoin compound.

A Paragraph IV strategy would require:

1. A listed patent with a commercially meaningful remaining term.
2. A noninfringement, invalidity, or unenforceability position.
3. Sufficient expected market value to justify litigation.
4. A launch opportunity that is not neutralized by other approved generic suppliers.
5. Manufacturing and bioequivalence data capable of supporting an ANDA approval.

For this product, the economic value of a first-to-file or first-approved position may be limited by the number of existing competitors. A Paragraph IV filing has greater value when paired with a differentiated formulation, supply advantage, or institutional contract strategy.

What generic launch risks exist?

Generic launch risk is operational rather than centered on molecule-level patent protection.

Risk	Impact	Mitigation
Poor dissolution matching	ANDA delay or additional studies	Control particle size, lubricant level, and granulation conditions
Blend segregation	Content-uniformity failure	Use engineered particles and validated blending
Moisture sensitivity	Stability failures	Use controlled humidity, suitable shell, and protective packaging
Capsule-shell variability	Dissolution and appearance changes	Qualify multiple shell suppliers
Excipient supply interruption	Batch delays	Dual-source lactose, starch, lubricant, and capsule shells
Commodity pricing	Margin compression	Simplify the formulation and secure long-term supply
Nitrofurantoin safety restrictions	Reduced prescribing in certain patients	Maintain accurate labeling and targeted market positioning
Regulatory changes	Regional relabeling or reformulation	Avoid unnecessary colorants and restricted materials

Nitrofurantoin also has renal-function limitations and important pulmonary, hepatic, neurologic, and hypersensitivity warnings. Those restrictions can affect prescriber adoption and institutional formularies.[1]

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can pursue several opportunities even when the drug itself is commoditized.

High-functionality excipient systems

A pre-engineered blend combining filler, binder, disintegrant, and glidant can reduce development time and manufacturing variability. The product should be optimized for low-dose, poorly soluble actives and validated against nitrofurantoin dissolution requirements.

Lactose-free platforms

A lactose-free filler system can support private-label, specialty-pharmacy, and export opportunities. The strongest commercial case is a formulation that maintains capsule size, density, dissolution, and cost near the reference product.

Capsule-shell systems

HPMC capsules, low-moisture gelatin capsules, and colorant-free shells can provide differentiation. Shell suppliers can create value through controlled moisture transmission, rapid dissolution, improved machine compatibility, and multi-region regulatory acceptability.

Particle-engineering services

Contract development organizations can offer micronization, controlled crystallization, sieving, blending, and analytical characterization for the monohydrate and macrocrystalline fractions. This is a more defensible service opportunity than selling standard excipients alone.

Stability and packaging solutions

Alu-Alu blister packaging, high-barrier bottles, desiccant systems, and moisture-controlled filling can improve shelf-life performance. Packaging differentiation is useful when a manufacturer exports to hot and humid climates or seeks to reduce recalls related to stability excursions.

How does nitrofurantoin compare with other urinary antibacterials?

Nitrofurantoin competes with trimethoprim-sulfamethoxazole, fosfomycin, pivmecillinam in some markets, and selected beta-lactams. Its commercial position depends on local resistance patterns, treatment guidelines, renal restrictions, dosage convenience, and price.

Product	Main commercial advantage	Main limitation
Nitrofurantoin monohydrate/macrocrystalline	Established lower-UTI use and low generic cost	Limited tissue penetration and renal restrictions
Fosfomycin	Single-dose option in many markets	Variable susceptibility and higher unit cost
Trimethoprim-sulfamethoxazole	Broad historical use and oral convenience	Resistance and allergy concerns
Oral beta-lactams	Familiar prescribing and multiple strengths	Often lower effectiveness for uncomplicated cystitis

The product has little biosimilar risk because biosimilar regulation applies to biologic products, not small-molecule nitrofurantoin. Its competitive risk comes from other oral antibacterials and from changes in antimicrobial stewardship.

What patent litigation and settlement issues affect the product?

No major current litigation or settlement should be assumed solely from the drug’s historical brand status. A current entrant must separately review:

• Orange Book-listed patents
• Federal Hatch-Waxman complaints
• ANDA litigation involving the reference product
• Settlement agreements affecting launch dates
• Patent assignments and licensing records
• Regulatory exclusivity attached to any newer formulation

For a mature generic, litigation economics are usually unfavorable unless the patent has a meaningful remaining term or the challenger expects a first-to-market advantage. Licensing may be more practical for a manufacturing process, specialized capsule technology, or regional distribution arrangement than for the expired core drug concept.

How strong is the patent estate for nitrofurantoin monohydrate/macrocrystalline?

The legacy patent estate is weak as a barrier to ordinary generic capsules. Potentially stronger protection can arise from narrowly defined formulation or manufacturing claims, but those claims must show technical differentiation and withstand obviousness scrutiny.

A practical strength assessment is:

Patent category	Relative strength
Nitrofurantoin compound claims	Very low due to age
Conventional capsule excipient claims	Low
Basic monohydrate/macrocrystalline combination	Low to moderate, depending on claim scope and prior art
Narrow particle-size or dissolution claims	Moderate if supported by unexpected results
Novel pediatric or modified-release dosage form	Moderate to high if clinically differentiated
Manufacturing process claims	Moderate where process controls produce reproducible, non-obvious results

What is the revenue exposure for manufacturers?

Revenue exposure is typically moderate at the product level and high at the portfolio level. Nitrofurantoin capsules are inexpensive generic products, but they can provide recurring volume through retail, mail-order, hospital, and government channels.

Margin depends on:

• API procurement cost
• Capsule-fill efficiency
• Batch size
• Number of competitors
• Contract pricing
• Product availability
• Recall history
• Manufacturing-site redundancy

The most attractive commercial model is usually a reliable, low-cost supply platform with multiple strengths and geographic registrations. A standalone premium-price strategy is difficult without a clinically meaningful dosage-form benefit.

Key Takeaways

• Nitrofurantoin monohydrate/macrocrystalline is a mature small-molecule generic market with little expected value from legacy molecule patents.
• The formulation contains two nitrofurantoin physical forms and requires tight control of particle size, blend uniformity, dissolution, and moisture.
• Core excipient opportunities involve lactose-free systems, HPMC capsules, colorant reduction, pre-engineered blends, and supply-chain redundancy.
• Formulation and process patents can have value only when they establish a defensible technical effect.
• Paragraph IV litigation is likely to be selective because the market is old and competitive.
• There is no biosimilar risk; competitive pressure comes from other generic antibiotics and prescribing restrictions.
• Commercial success depends more on manufacturing reliability, regulatory execution, and procurement economics than on broad patent exclusivity.
• The strongest opportunities are differentiated excipient systems, global capsule platforms, particle-engineering services, and robust packaging for international distribution.

FAQs

Can nitrofurantoin monohydrate/macrocrystalline be formulated without lactose?

Yes. Lactose can be replaced with materials such as mannitol, microcrystalline cellulose, or selected phosphate and starch-based fillers. The replacement must preserve capsule fill, dissolution, stability, and bioequivalence performance.

Is an HPMC capsule suitable for nitrofurantoin monohydrate/macrocrystalline?

An HPMC capsule can be technically suitable, but the shell changes moisture transfer, mechanical properties, and dissolution behavior. Comparative performance and regulatory assessment are required.

Does nitrofurantoin require a special controlled-release excipient?

The standard monohydrate/macrocrystalline product does not depend on a conventional polymeric extended-release matrix. Its performance is primarily linked to the physical forms of nitrofurantoin, particle characteristics, and the capsule-fill system.

Can a manufacturer patent a new nitrofurantoin excipient combination?

Potentially, but broad claims covering routine excipient substitutions are vulnerable to prior-art and obviousness challenges. Patent strength improves when the combination produces unexpected dissolution, stability, exposure, or tolerability results.

What is the best commercial differentiation strategy for this product?

The strongest strategy is usually a reliable, globally acceptable capsule platform with controlled particle engineering, stable supply, optional lactose-free or animal-free presentations, and competitive manufacturing cost.

References

1. U.S. Food and Drug Administration. (2023). Macrobid: Nitrofurantoin monohydrate/macrocrystals capsule prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. Washington, DC: U.S. Department of Health and Human Services.
3. U.S. Food and Drug Administration. (2022). Guidance for industry: ANDAs for certain highly soluble drug substances. Washington, DC: U.S. Department of Health and Human Services.
4. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. Washington, DC: U.S. Department of Health and Human Services.